Latest Breaking News On - Head of global development - Page 1 : comparemela.com

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesJosh smileyHarald reinhartZai lab forwardZai labExchange commissionZai lab limitedHead of global developmentChief operating officerGlobal developmentInfectious diseasesPsoriasis area severity indexPrivate securities litigation reform act

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on.

Hong kongNew zealandRepublic ofUnited statesHarald reinhartMatt ronsheimAcinetobacter baumanniiCenters for diseaseHead of global developmentZai lab limitedZai labSecurities exchangeInnoviva incDrug administrationZai lab forwardExchange commission

Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+

Zai Lab Ltd. (ZLAB) and Innoviva Specialty Therapeutics announced Monday that China's National Medical Products Administration or NMPA has approved Zai Lab's New Drug Application for XACDURO (sulbactam-durlobactam) to treat hospital-acquired and ventilator-associated pneumonia caused by Acinetobacter baumannii-calcoaceticus complex in China.

Harald reinhartEntasis therapeutics incChina national medical products administrationHead of global developmentZai labZai lab new drug applicationDrug administrationZai lab ltdMore such health newsWorld health organizationInnoviva specialty therapeuticsNational medical products administrationNew drug applicationGreater chinaGlobal developmentInfectious diseases

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China

Innoviva : Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam Durlobactam or SUL DUR) for Hospital Acquired and Ventilator Associated Pneumonia Caused by Acinetobacter Baumannii Calcoaceticus Complex in China
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesNew zealandUnited kingdomRepublic ofAcinetobacter baumanniiHarald reinhartMatt ronsheimDrug administrationZai lab limitedHealth organizationCenters for diseaseZai lab new drug applicationEntasis therapeutics incZai labHead of global development

Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

Czech republicUnited statesAndrew zhuLouise chenYigal nochomovitzJosh smileyHarald reinhartLinhai zhao goldman sachsJonathan wangChristine chiouJack linJonathan changAnupam ramaYajing chenMichael yeeRafael amado